Keywords: Australia, Crestor patent decision, AstraZeneca, PBS savings, Misuse of patents, GMiA

Further savings expected following Australian Crestor patent decision, says GMiA

Article | 07 March 2013

Print This

In a decision brought down by the Australian Federal Court earlier this week, suppliers of generic medicines are a step ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in